Exclusion criteria:
- Patients with metastatic involvement of any region,
- Patients with any other malignancy.
Nineteen patients who were planned to be treated with BCG for high-grade
NMIBC between February 2016 and November 2017 and 19 healthy
participants for comparison were enrolled in the study. Healthy
participants were selected randomly, and urinary ultrasonography and
urinary analyses were performed to exclude bladder malignancies.